496 related articles for article (PubMed ID: 33229553)
1. Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.
Yueh MF; He F; Chen C; Vu C; Tripathi A; Knight R; Karin M; Chen S; Tukey RH
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31259-31266. PubMed ID: 33229553
[TBL] [Abstract][Full Text] [Related]
2. Folic acid attenuates high-fat diet-induced steatohepatitis
Xin FZ; Zhao ZH; Zhang RN; Pan Q; Gong ZZ; Sun C; Fan JG
World J Gastroenterol; 2020 May; 26(18):2203-2220. PubMed ID: 32476787
[TBL] [Abstract][Full Text] [Related]
3. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K; Yamaguchi K; Seko Y; Okishio S; Ishiba H; Tochiki N; Takahashi A; Kataoka S; Okuda K; Liu Y; Fujii H; Umemura A; Moriguchi M; Okanoue T; Itoh Y
Lab Invest; 2022 Mar; 102(3):281-289. PubMed ID: 34732847
[TBL] [Abstract][Full Text] [Related]
5. High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis.
Chen X; Acquaah-Mensah GK; Denning KL; Peterson JM; Wang K; Denvir J; Hong F; Cederbaum AI; Lu Y
Am J Physiol Gastrointest Liver Physiol; 2020 Nov; 319(5):G626-G635. PubMed ID: 32877213
[TBL] [Abstract][Full Text] [Related]
6. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
7. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
Fisher FM; Chui PC; Nasser IA; Popov Y; Cunniff JC; Lundasen T; Kharitonenkov A; Schuppan D; Flier JS; Maratos-Flier E
Gastroenterology; 2014 Nov; 147(5):1073-83.e6. PubMed ID: 25083607
[TBL] [Abstract][Full Text] [Related]
9. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity.
Wang L; Mazagova M; Pan C; Yang S; Brandl K; Liu J; Reilly SM; Wang Y; Miao Z; Loomba R; Lu N; Guo Q; Liu J; Yu RT; Downes M; Evans RM; Brenner DA; Saltiel AR; Beutler B; Schnabl B
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15184-15193. PubMed ID: 31289229
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
12. Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response.
Yang Q; Shu F; Gong J; Ding P; Cheng R; Li J; Tong R; Ding L; Sun H; Huang W; Wang Z; Yang L
J Ethnopharmacol; 2020 Jun; 255():112556. PubMed ID: 31926984
[TBL] [Abstract][Full Text] [Related]
13. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Schumacher JD; Kong B; Pan Y; Zhan L; Sun R; Aa J; Rizzolo D; Richardson JR; Chen A; Goedken M; Aleksunes LM; Laskin DL; Guo GL
Toxicol Appl Pharmacol; 2017 Sep; 330():1-8. PubMed ID: 28673684
[TBL] [Abstract][Full Text] [Related]
14. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
16. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
[TBL] [Abstract][Full Text] [Related]
17. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
18. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling.
Liu X; Zhang Y; Ma C; Lin J; Du J
Mol Biol Rep; 2022 Apr; 49(4):3113-3122. PubMed ID: 35107741
[TBL] [Abstract][Full Text] [Related]
19. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
